Inflammatory Complications of Intravitreal Anti-VEGF Injections.
TLDR
The most commonly used anti-vascular endothelial growth factor (anti-VEGF) agents are bevacizumab, ranibizumabi, aflibercept, and brolucizumaba.Abstract:
Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is a commonly used therapy for numerous retinal diseases. The most commonly used of these medications are bevacizumab, ranibizumab, aflibercept, and brolucizumab. However, intravitreal administration of these agents is also associated with several inflammatory and non-inflammatory adverse events. The three inflammatory adverse events are sterile intraocular inflammation, brolucizumab-associated retinal vasculitis, and post-injection endophthalmitis. This narrative review summarizes the current literature regarding these conditions, including their epidemiology, presentation, management, outcomes, and pathogenesis. The inflammatory adverse events also share a number of overlapping features, which can make them difficult to discern from one another in a clinical context. This review discusses certain distinguishing features of these conditions that may aid providers in discerning between them and establishing the correct diagnosis.read more
Citations
More filters
Journal ArticleDOI
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD).
Prem Nimesh Patel,Veeral Sheth +1 more
TL;DR: In this paper, the authors summarize all the newer molecules, their pivotal clinical trial results, and their unique mechanisms of action; these include longer-acting agents, combination strategies, sustained release, and genetic therapies.
Journal ArticleDOI
Synthesis and Characterization of Novel Succinyl Chitosan-Dexamethasone Conjugates for Potential Intravitreal Dexamethasone Delivery.
Natallia V. Dubashynskaya,Anton N. Bokatyi,Alexey Golovkin,Igor Kudryavtsev,Maria Serebryakova,Andrey S. Trulioff,Yaroslav A. Dubrovskii,Yury A. Skorik +7 more
TL;DR: In this article, a two-step synthesis of dexamethasone (DEX) conjugates based on the natural polysaccharide chitosan (CS) is presented.
Journal ArticleDOI
Recent Advances in Hydrogels: Ophthalmic Applications in Cell Delivery, Vitreous Substitutes, and Ocular Adhesives
TL;DR: The use of hydrogels in ocular therapy has been a critical focus in overcoming the limitations of current treatments as discussed by the authors, such as the potential for surgically induced astigmatism or wound leakage.
Journal ArticleDOI
Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
TL;DR: In this article , the authors provide an overview of current and emerging anti-VEGF agents for the treatment of age-related macular degeneration (nAMD) in the elderly population.
Journal ArticleDOI
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ajmal Ahmad,Mohd Imtiaz Nawaz +1 more
TL;DR: Recent developments toward the delineation of the functional biology of VEGF and the role of anti-VEGF strategies in the management of tumor and eye pathologies are focused on.
References
More filters
Journal ArticleDOI
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.
TL;DR: In this article, a process of standardizing the methods for reporting clinical data in the field of uveitis has been discussed, and the results used to develop a series of proposals to better standardize the use of these entities.
Journal ArticleDOI
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F. Martin,Maureen G. Maguire,Gui-Shuang Ying,Juan E. Grunwald,Stuart L. Fine,Glenn J. Jaffe +5 more
TL;DR: Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizuab administered monthly, although the comparison between bevacizumAB as needed and monthly bevicizumabs was inconclusive.
Journal ArticleDOI
The safety and side effects of monoclonal antibodies
TL;DR: Some of the adverse effects encountered with mAb therapies are reviewed, and advances in preclinical testing and antibody technology aimed at minimizing the risk of these events are discussed.
Journal ArticleDOI
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
TL;DR: The vitreous half-life of 1.25 mg intravitreal bevacizumab (Avastin) is 4.32 days in a rabbit eye, compared with 4.88 days and 6.86 days for the aqueous and serum values, respectively.
Journal ArticleDOI
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
TL;DR: In this paper, the authors evaluated the pharmacokinetic and serum bioavailability of ranibizumab after a single intravitreal (ITV) or intravenous (IV) dose in cynomolgus monkeys.